2021
Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy
Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.Peer-Reviewed Original ResearchConceptsPathologic complete responseResidual cancerClinical trialsAdjuvant therapyExcellent long-term disease-free survivalLong-term disease-free survivalAxillary lymph node dissectionHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Post-mastectomy breastSystemic adjuvant therapyInternal mammary nodesLymph node dissectionNeoadjuvant systemic therapyDisease-free survivalGrowth factor receptor 2Minimal residual disease monitoringRecurrence-free survivalType of surgeryPivotal clinical trialsOngoing clinical trialsFactor receptor 2Residual disease monitoringAccurate prognostic estimatesPatterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.Peer-Reviewed Original ResearchConceptsPrior endocrine therapyEndocrine therapyMetastatic breast cancerEffective treatment optionTreatment optionsBreast cancerMedian treatmentMedian OSEE therapyHormone receptor-positive HER2-negative metastatic breast cancerMultivariable Cox proportional hazards regression analysisHER2-negative metastatic breast cancerPrior treatmentCox proportional hazards regression analysisFirst-line therapy initiationProportional hazards regression analysisPrior treatment optionsLines of therapyProportion of patientsKaplan-Meier methodHazards regression analysisPatterns of treatmentElectronic health record-derived dataClinical trial dataOS benefit
2014
Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence
Rozenblit M, Suarez-Farinas M, Shemer A, Khattri S, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, Krueger JG, Guttman-Yassky E. Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. Journal Of Allergy And Clinical Immunology 2014, 134: 955-957. PMID: 24996261, PMCID: PMC4281263, DOI: 10.1016/j.jaci.2014.05.024.Peer-Reviewed Original ResearchCyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology
Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, de Guzman Strong C, Gonzalez J, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. Journal Of Allergy And Clinical Immunology 2014, 133: 1626-1634. PMID: 24786238, PMCID: PMC4122665, DOI: 10.1016/j.jaci.2014.03.003.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBiomarkersCluster AnalysisCyclosporineDendritic CellsDermatitis, AtopicEpidermisFemaleGene Expression ProfilingGene Expression RegulationHumansHyperplasiaImmunosuppressive AgentsInflammationMaleMiddle AgedPhenotypeSignal TransductionT-Lymphocyte SubsetsTreatment OutcomeYoung AdultConceptsClinical improvementAtopic dermatitisCytokine activationEpidermal alterationsAD skin lesionsEpidermal pathologyWeeks of treatmentT cell cytokinesCommon inflammatory diseaseSystemic immunosuppressantsSCORAD scoreNonlesional skinWeek 12Inflammatory pathwaysTissue inflammationBiopsy specimensInflammatory diseasesSignificant gene expression changesSevere diseaseEpidermal hyperplasiaImmunohistochemistry studiesSkin lesionsSpecific cytokinesWeek 2CsA effects
2003
Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis
Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2003, 14: 7-16. PMID: 14578093, DOI: 10.1080/jdt.14.s2.7.16.Peer-Reviewed Original ResearchRetrospective study of the efficacy of narrowband UVB and acitretin
Spuls P, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. Journal Of Dermatological Treatment 2003, 14: 17-20. PMID: 14578094, DOI: 10.1080/jdt.14.s2.17.20.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinHumansKeratolytic AgentsPsoriasisRetrospective StudiesTreatment OutcomeUltraviolet TherapyConceptsCombination of acitretinNarrowband UVBPlaque psoriasisUltraviolet BBroadband ultraviolet BLow-dose acitretinUVB three timesMajority of patientsUltraviolet B treatmentDose acitretinOral acitretinSerum lipidsTreat patientsTreat groupNumber of treatmentsRetrospective studyBroadband UVBRetrospective analysisAcitretinSide effectsUVB resultsPatientsPhototherapy treatmentMonotherapyPsoriasisRetrospective study of the efficacy of narrowband UVB and acitretin
Spuls P, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. Journal Of Dermatological Treatment 2003, 14: 17-20. DOI: 10.1080/738528794.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinHumansKeratolytic AgentsPsoriasisRetrospective StudiesTreatment OutcomeUltraviolet TherapyConceptsCombination of acitretinNarrowband UVBPlaque psoriasisUltraviolet BBroadband ultraviolet BLow-dose acitretinUVB three timesMajority of patientsUltraviolet B treatmentDose acitretinOral acitretinSerum lipidsTreat patientsTreat groupNumber of treatmentsRetrospective studyBroadband UVBRetrospective analysisAcitretinSide effectsUVB resultsPatientsPhototherapy treatmentMonotherapyPsoriasis